Related Experiment Video
Updated: Sep 13, 2025
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
20.5K
Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy.
Cory M Richman1,2,3, Alexandra Rasnitsyn1,2,3, Borja L Holgado1,2
1The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Canada.
Cancer Research
|July 25, 2025
Summary
Group 3 medulloblastoma is aggressive. Targeting carbonic anhydrase 4 (CA4) with acetazolamide may improve radiotherapy efficacy and reduce recurrence in pediatric patients.
Area of Science:
- Pediatric oncology
- Molecular biology
- Cancer research
Background:
- Group 3 medulloblastoma is the most aggressive subtype, frequently recurring with metastases.
- Current treatments lack survival benefits for recurrent medulloblastoma.
- Understanding resistance mechanisms is crucial for improving outcomes.
Purpose of the Study:
- Identify actionable targets and biomarkers for Group 3 medulloblastoma.
- Reduce recurrence risk and improve survival in newly diagnosed patients.
- Investigate mechanisms of radioresistance.
Main Methods:
- Utilized clinically relevant mouse models of Group 3 medulloblastoma.
- Employed CT-guided fractionated radiotherapy.
- Compared gene expression profiles of recurrent vs. treatment-naïve tumors.
- Investigated carbonic anhydrase 4 (CA4) expression and function.
Main Results:
- Radiotherapy induced radioresistant subpopulations driving recurrence.
- Discovered a prognostic gene signature for radioresistance and poor prognosis.
- Elevated CA4 expression in recurrent tumors.
- CA4 modulation affected radiotherapy resistance; acetazolamide showed potential as a radiosensitizer.
Conclusions:
- CA4 is a potential therapeutic target in Group 3 medulloblastoma.
- Acetazolamide may enhance radiotherapy efficacy, reducing recurrence.
- Findings suggest improved treatment strategies for newly diagnosed pediatric medulloblastoma.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
322
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
322
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
262
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
262